Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We are delighted to announce that four of our researchers have been awarded the title of Professor, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine, University of Oxford.

George Warimwe, Yoel Lubell, Frank Smithuis and Lorenz von Seidlein

These are the staff awarded full professor status in the most recent recognition of distinction process:

George Warimwe, Professor of Vaccinology

Yoel Lubell, Professor of Global Health

Frank Smithuis, Professor of Tropical Medicine

Lorenz von Seidlein, Professor of Global Health

Professor Yoel Lubell leads the Economics and Implementation Research Group at the MORU Mathematical and Economic Modelling Group, based in Bangkok, Thailand. His research focuses on the evaluation of diagnostics, treatments and vaccines for infectious diseases, with the aim of providing guidance on malaria elimination and control of artemisinin resistance in the Mekong region.

Professor Frank Smithuis is the director of MOCRU, our Myanmar Oxford Clinical Research Unit. MOCRU involves a network of 18 clinics and 2040 community health workers in remote areas.
Most research questions originate from the day to day health issues in this network. Research interests include the epidemiology and management of artemisinin resistant malaria, the aetiology and management of fever, and the management of TB, HIV and opportunistic infections.

Professor Lorenz von Seidlein coordinates MORU’s Targeted Malaria Elimination study, which seeks to eliminate artemisinin resistant falciparum malaria by treating entire communities that have significant levels of subclinical malaria parasite infections and transmission with the antimalarial dihydroartemisinin-piperaquine.

Professor George Warimwe works on viral infections transmitted between humans and animals in Africa, developing vaccines for their control. An example is Rift Valley Fever - a mosquito-borne viral illness that primarily affects humans and livestock (sheep, goats, cattle) in Africa – for which Prof. Warimwe has developed a novel chimpanzee adenovirus vectored vaccine, that is highly efficacious in livestock and is currently in human phase I clinical trials. His previous work includes a similar One Health vaccine for use against Middle East Respiratory Syndrome (MERS) in camels and humans, with his veterinary research programmes continuing to inform advances in human vaccinology.
Prof Warimwe’s other work includes addressing the global shortage in Yellow Fever (YF) vaccine supply through leadership of trials to evaluate the utility of fractional vaccine dosing for epidemic control. Findings from this work will have a major impact on the number of doses that can be given based on the current global stock of YF vaccine and the number of doses that are produced for future use. His recent work on COVID-19 serology in Kenya has informed decisions on the national pandemic response and remains one of the most comprehensive COVID-19 seroepidemiological programmes in Africa to date.

“I’m truly honoured by this recognition. It is testimony to the excellent mentorship received over the years and the immense contribution to vaccine R&D in Africa by the team of amazingly talented scientists that work with me in Kenya and Oxford” said Prof Warimwe.

Please join us in congratulating George, Frank, Lorenz and Yoel on this marvellous and richly deserved achievement!!

Read the News on the Nuffield Department of Medicine website

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Celebrating Women and Girls in Science

Women have made significant contribution in research despite the numerous challenges they face. To celebrate the women and girls in science we asked some women at KEMRI Wellcome Trust Research programme to share their journey in research, their achievements, and a word of advice to fellow women in science.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.